Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501650 | 0.92 | USP30 (0.44) | USP30DGAT1HDAC6HDAC1CHEK1 | |
| SCHEMBL6495134 | 0.90 | USP30 (0.44) | USP30DGAT1HDAC6HDAC1ROCK1 | |
| SCHEMBL6489724 | 0.90 | USP30 (0.53) | USP30DGAT1HDAC6HDAC1 | |
| SCHEMBL6498247 | 0.89 | USP30 (0.45) | USP30DGAT1HDAC6HDAC1 | |
| SCHEMBL6499855 | 0.89 | HDAC1 (0.45) | USP30DGAT1HDAC6HDAC1CHEK1 | |
| SCHEMBL6490465 | 0.89 | HDAC6 (0.45) | USP30DGAT1HDAC6HDAC1 | |
| SCHEMBL6496553 | 0.86 | HDAC1 (0.48) | USP30DGAT1HDAC6HDAC1CSNK2A1 | |
| SCHEMBL6485776 | 0.85 | DGAT1 (0.47) | USP30DGAT1ROCK1 | |
| SCHEMBL6499800 | 0.85 | USP30 (0.44) | USP30DGAT1CYP3A4HDAC6HDAC1 | |
| SCHEMBL6487733 | 0.84 | USP30 (0.43) | USP30DGAT1HDAC6HDAC1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | USP30 3442/4885DGAT1 2495/4885CYP3A4 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.